Fanapt Commercial Growth
Fanapt's commercial growth has accelerated, reaching multi-year highs with weekly prescriptions surpassing 2,000 at the end of April. Total prescriptions increased by approximately 14% and net product sales increased by 14% compared to the same quarter last year.
Pipeline Development Success
Recent new drug application filings for Tradipitant and Bysanti indicate a strong and productive research and development pipeline, with multiple drugs in various stages of regulatory approval.
Expansion of Sales Force
Vanda has expanded its psychiatry sales force to approximately 300 representatives to support the growth of Fanapt and other products.
Maintained Market Share
HETLIOZ continues to retain the largest portion of market share despite generic competition for over two years.
Financial Guidance and Cash Reserves
Vanda expects total revenues from Fanapt, HETLIOZ, and PONVORY of between $210 million and $250 million. Year-end 2025 cash is projected to be between $280 million and $320 million.